Our Key Figures

 

21 000 employees

in 148 countries, including 4 800 in France.

 

5 major R&D areas

cardiovascular and immune-inflammatory diseases, neuropsychiatric disorders, oncology and diabetes.

 

64 Million patients

treated daily with Servier medicinal products and generics.

 

47 Servier drugs

on the global market.

 

34 drug candidates

in clinical research and development, including 9 fixed-dose combinations.

 

15 international centres of clinical development

and 3 research centres.

 

15 chemical and pharmaceutical production sites

chemistry and pharmaceuticals worldwide.

 

4 Billion euro turnover

comprising 2.8 billion euros for Servier and 1.2 billion euros for generics.

 

25% of turnover from Servier drugs is invested in R&D

excluding generics.

 

No. 2 pharmaceutical company in France

no. 30 in the world; 3 research centres including 2 in France.

 

No. 1 in cardiology in France

no. 2 in Europe, No. 8 in the world.

 

 

2nd leading preferred partner for research centres conducting clinical trials

According to CenterWatch rankings from March 2017, based on a total of 23 pharmaceutical companies.

 

Servier earned the highest score of A3++

As in previous years, this high score represents excellence in honoring financial commitments.

 

Participation reached 48% of the trade balance surplus in France

In pharmaceuticals and fine chemicals, amounting to 1.42 billion euros.